ArticleMicrobial cell factories2023
Beneficial effects of GABA-producing potential probiotic Limosilactobacillus fermentum L18 of human origin on intestinal permeability and human gut microbiota.
Article in Microbial cell factories, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 27 citations in OpenAlex.
- Postbiotic Metabolites: Therapeutic Potential, Industrial Applications, Market Dynamics, and Regulatory Frameworks.Probiotics and antimicrobial proteins · 2026Review
- The neurobiotic sense: emerging pathways of microbial detection and gut-brain communication.Pflugers Archiv : European journal of physiology · 2026Review
- Comprehensive Genomic Characterization and Probiotic Properties Evaluation of Limosilactobacillus fermentum JAC 231 Isolated from Vaginal Microbiota.Probiotics and antimicrobial proteins · 2026Article
- Beyond the Brain: GABAergic Signaling as a Peripheral Modulator of Skin Barrier Immunity.International journal of molecular sciences · 2026Review
- Comparative genomics reveals population structure and functional differentiation in Limosilactobacillus fermentum.Scientific reports · 2026Article
- Probiotic Bacteria in Stimulating Human Physiological Responses: Metabolic Function and Overall Health.Foods (Basel, Switzerland) · 2026Review
- Multifactorial Neuroprotective Potential of γ-Aminobutyric acid-Producing Potential Probiotics Against Stress Induced Neuronal Cell Lines.Probiotics and antimicrobial proteins · 2026Article
- GABA-Producing Bacteria as Potential Psychobiotics in Gut-Brain Axis Regulation.International journal of molecular sciences · 2026Review
- The Microbiota-Gut-Brain Axis in Insomnia: Mechanisms and Intervention Strategies.Life (Basel, Switzerland) · 2026Review
- Safety Assessment of GABA-Producing Levilactobacillus brevis LAB6 MTCC 25662 and Its Anti-inflammatory Effects in Murine Macrophages.Probiotics and antimicrobial proteins · 2026Article
- Article
- Lactobacilli, best allies of mental health: a probiogenomic approach to identify potential psychobiotic strains.Current research in food science · 2026Article
- Mental health and gut-brain crosstalk: implications for depression and Alzheimer's disease.Neuroscience applied · 2026Review
- Characteristics of gut microbiota dysbiosis in patients with depression: a visual analysis of knowledge maps.Frontiers in microbiology · 2026Review
- Microbiota Gut-Brain Axis and Autism Spectrum Disorder: Mechanisms and Therapeutic Perspectives.Nutrients · 2025Review
- Article
- The Gut Microbiota-anxiety Connection: Evidence, Mechanisms, and Therapeutic Strategies.Current medicinal chemistry · 2025Review
- Advancements in the investigation of gut microbiota-based strategies for stroke prevention and treatment.Frontiers in immunology · 2025Review
- Altered gut microbial networks and metabolic pathways in multiple system atrophy: a comparative 16S rRNA study.Frontiers in neuroscience · 2025Article
- The microbiota-gut-brain axis in depression: unraveling the relationships and therapeutic opportunities.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundGamma-aminobutyric acid (GABA) is a non-protein amino acid with neuroinhibitory, antidiabetic, and antihypertensive properties and is used as a drug for treating anxiety and depression. Some strains of lactobacilli are known to produce GABA and strengthen the gut barrier function which play an important role in ameliorating the effects caused by the pathogen on the gut barrier. The probiotic bacteria are also known to modulate the human fecal microbiota, however, the role of GABA-producing strains on the gut epithelium permeability and gut microbiota is not known.
resultsIn this study, we report the production of high levels of GABA by potential probiotic bacterium Limosilactobacillus fermentum L18 for the first time. The kinetics of the production of GABA by L18 showed that the maximum production of GABA in the culture supernatant (CS) occurred at 24 h, whereas in fermented milk it took 48 h of fermentation. The effect of L18 on the restoration of lipopolysaccharide (LPS)-disrupted intestinal cell membrane permeability in Caco-2 monolayers showed that it significantly restored the transepithelial electrical resistance (TEER) values, by significantly increasing the levels of junction proteins, occludin and E-cadherin in L18 and LPS-treated Caco-2 cells as compared to only LPS-treated cells. The effect of GABA-secreting L18 on the metataxonome of human stool samples from healthy individuals was investigated by a batch fermentor that mimics the conditions of the human colon. Although, no differences were observed in the α and β diversities of the L18-treated and untreated samples at 24 h, the relative abundances of bacterial families Lactobacillaceae and Bifidobacteriaceae increased in the L18-treated group, but both decreased in the untreated groups. On the other hand, the relative abundance of Enterobacteriaceae decreased in the L18 samples but it increased in the untreated samples.
conclusionThese results indicate that Li. fermentum L18 is a promising GABA-secreting strain that strengthens the gut epithelial barrier by increasing junction protein concentrations and positively modulating the gut microbiota. It has the potential to be used as a psychobiotic or for the production of functional foods for the management of anxiety-related illnesses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.